Jane Yang is a Reporter at Knowridge Science Report. She covers a range of topics including science, technology, and current events, with a focus on how these themes intersect with societal issues. Jane's work has been featured in notable publications such as The Epoch Times, Wilson Sonsini Goodrich & Rosati, CauseACTION Clarion, Daily Mail, San Diego Metro Magazine, and NEOMERS.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Escondido, United States (Local)
Not enough data
Not enough data
Jane Yang's coverage heavily focuses on citing data and scientific themes, particularly in the areas of medical research, health conditions, treatment development, disease prevention, and risk factors. She appears to be interested in covering studies that provide new insights into various health-related topics.
Given her focus on scientific themes and reliance on data citations, Jane is likely to respond well to pitches that offer access to or insights from reputable researchers who can discuss the methodology used in their studies or explain the implications of their findings. Additionally, she may appreciate pitches that highlight cutting-edge developments in medical research or treatment approaches for different health conditions.
As Jane does not have a specific geographic focus mentioned but covers broad scientific and healthcare topics with a global perspective, experts from various regions could reach out to provide valuable insights aligned with her coverage interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jennifer B Dennison, Sara Khoramisarvestani, Hamid Rudsari, Jody Vykoukal, Edwin Ostrin, Sara Ansari, Jane Yang, Nicole Kettner, Iakovos Toumazis, Johannes Fahrmann, Samir Hanash, Ehsan Irajizad
Abstract Purpose: We report a blinded validation study of a ten-protein marker blood test for assessing risk of developing or harboring nine common cancers in a prospective lung cancer screening cohort.
On November 17, 2025, Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, announced it raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform. This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million. Wilson Sonsini Goodrich & Rosati advised Solve Therapeutics on patent matters related to the transaction.
